Press Releases

Date Title
Toggle Summary Aeglea BioTherapeutics Announces Oral Presentation of Preclinical Data on New Pipeline Therapeutic for Cystinuria at 2018 American Society of Nephrology
AUSTIN, Texas , Sept. 17, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced that it will deliver an oral
Toggle Summary Aeglea BioTherapeutics Announces Positive Interim Clinical Data and Completion of Enrollment for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency
Exceeded Enrollment Target with 15 Patients in Phase 1/2 Trial Additional Interim Data to be Presented at ASHG Conference in October 2018 Company Plans to Announce Pivotal Trial Design in Q4 2018 and Initiate Pivotal Trial in 1H 2019 Company to Host Clinical Update Conference Call Today at 8:30
Toggle Summary Aeglea BioTherapeutics to Present at 2018 Wells Fargo Healthcare Conference
Company to Webcast Presentation on Wednesday, September 5 at 10:50 am ET AUSTIN, Texas , Aug. 28, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic
Toggle Summary Aeglea BioTherapeutics to Present New Interim Phase 1/2 Clinical Trial Data in Arginase 1 Deficiency at 2018 SSIEM Annual Symposium
Company to Host Clinical Update Conference Call on September 4 at 8:30 a.m. ET AUSTIN, Texas , Aug. 27, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare
Toggle Summary Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results
AUSTIN, Texas , Aug. 09, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today provided a corporate update and reported
Toggle Summary Aeglea BioTherapeutics Announces Fall 2018 Medical Conference Schedule
Company Will Provide New Interim Data for Pegzilarginase in Patients with Arginase 1 Deficiency Preclinical Efficacy Data of AEB4104 - a New Enzyme Approach - for the treatment of Homocystinuria Three-Conference Schedule Includes Five Abstract Acceptances Regarding Rare Genetic Disease and Cancer
Toggle Summary Aeglea BioTherapeutics Appoints Dr. Anthony G. Quinn as President and Chief Executive Officer
AUSTIN, Texas , July 19, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced the appointment of Anthony G.
Toggle Summary Aeglea BioTherapeutics Appoints Dr. Bryan Lawlis to Board of Directors
AUSTIN, Texas , July 16, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced the appointment of Bryan Lawlis ,
Toggle Summary Aeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AUSTIN, Texas , June 29, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced that the Compensation Committee of
Toggle Summary Aeglea BioTherapeutics to Present at UBS Global Healthcare Conference
Company to Webcast Presentation on Tuesday, May 22 at 8:30 a.m. ET AUSTIN, Texas , May 15, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic
Toggle Summary Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2018 Financial Results
AUSTIN, Texas , May 08, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today provided a corporate update and reported
Toggle Summary Aeglea BioTherapeutics Prices Public Offering of Common Stock
AUSTIN, Texas , April 18, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. , (Nasdaq:AGLE) a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced the pricing of its underwritten
Toggle Summary Aeglea BioTherapeutics Announces Proposed Public Offering of Common Stock
AUSTIN, Texas , April 17, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced that it has commenced an
Toggle Summary Aeglea BioTherapeutics Presents New Phase 1/2 Trial Data Demonstrating Clinically Relevant Treatment Effects in Arginase 1 Deficiency Patients at the 2018 ACMG Annual Clinical Genetics Meeting
Clinical Outcome Assessment Tools Detected and Quantified Baseline Abnormalities Clinically Relevant Improvement Seen in Multiple Neuromotor Tests Company to Host Clinical Update Conference Call Today at 8:30 a.m. ET AUSTIN, Texas , April 12, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc.
Toggle Summary Aeglea BioTherapeutics to Present Pegzilarginase Phase 1 Dose Escalation Data in Patients with Advanced Solid Tumors at 2018 AACR Annual Meeting
AUSTIN, Texas , April 05, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced that it will present Phase 1 dose